Calcific Tendinopathy of the Shoulder: The Strongest Case in Focused Wave Literature

If you are evaluating focused acoustic wave technology for your practice and want to start with the condition where the evidence is most defensible, this is it.

Calcific tendinopathy of the shoulder has the most robust randomized controlled trial evidence of any musculoskeletal indication in the focused wave literature. Multiple meta-analyses over the past 15 years show clinically significant improvements in pain and function — and unlike most soft-tissue indications, the treatment effect is visible on imaging. Calcium deposits go in. After treatment, many of them are partially or completely gone.

That is a rare thing in non-surgical orthopedic care, and it matters for how you build a practice around this technology.

What the Condition Actually Is

Calcific tendinopathy involves the deposition of calcium hydroxyapatite crystals within rotator cuff tendons, most commonly the supraspinatus. The presentation varies. Some patients experience acute, severe pain during active resorption. A meaningful subset develops chronic, treatment-resistant symptoms — night pain, limited overhead motion, failed conservative care — and that is the patient population where focused acoustic wave therapy has its clearest published role.

The natural history is unpredictable. Some deposits resorb spontaneously. Many do not. For patients who have been symptomatic for more than six months with a visible deposit and a failed cortisone injection, the traditional treatment ladder offers limited options between “keep waiting” and “consider surgery.”

What the Research Shows

Pain and Function

The evidence base for focused wave therapy in calcific tendinopathy is the largest and most consistent in the musculoskeletal focused wave literature. A 2024 systematic review and meta-analysis on focused wave therapy for rotator cuff tendinopathy summarized a large body of randomized trial evidence supporting clinically significant improvements in both pain and shoulder function. One systematic review reported success rates of approximately 88.5% in calcific cases specifically.

A 2014 systematic review published in the Annals of Internal Medicine evaluated high-energy focused wave therapy for chronic calcific tendinitis of the shoulder and concluded it demonstrated efficacy for this indication. The evidence has continued to accumulate since.

Calcium Deposit Resorption

This is what separates calcific tendinopathy from every other indication in this literature. Beyond pain outcomes, focused wave therapy produces measurable, imaging-documented changes to the deposit itself.

In one widely cited series, complete dissolution occurred in approximately 57.6% of patients, partial dissolution in 15.1%, and no change in 27.3%. A 2013 systematic review and meta-analysis on calcium resorption found pooled resorption ratios favoring focused wave therapy over control conditions across both complete and partial dissolution outcomes.

For a practice building a focused wave program, this is significant. Pre- and post-treatment imaging gives patients something tangible — a film showing the deposit before, a film showing partial or complete resorption after. In a treatment category where outcomes are usually self-reported, objective imaging change is a different category of evidence.

Comparison to Other Interventions

A 2023 systematic review and meta-analysis covering 27 studies and 2,212 patients compared operative and non-operative interventions for calcific tendinitis, including focused wave therapy, needle barbotage, and arthroscopic surgery. Both focused wave therapy and needling produced clinically significant improvements in pain and function. The authors concluded it was reasonable to trial focused wave therapy as a first-line option before surgical intervention.

That recommendation matters for how you position this in a referral network and in a conversation with a patient who has been sent to orthopedic surgery and wants to try something first.

Mechanism

The therapeutic mechanism in calcific tendinopathy is dual. Focused mechanical energy contributes directly to disruption and resorption of the calcium deposit. The broader tissue response — including angiogenesis and growth factor upregulation (Wang et al. documented VEGF increases of approximately 329% with focused wave therapy) — supports recovery of the underlying tendon. The treatment addresses the deposit and the tissue at the same time.

Who to Treat

Not every calcific tendinopathy patient is the same profile for focused wave therapy. 

The published literature points toward a clear target.

The textbook referral for this protocol is a patient in their late 40s or early 50s, chronic right shoulder pain, imaging showing a supraspinatus deposit in the 8–10 mm range, one or two cortisone injections behind them with diminishing returns, and an orthopedic referral they are motivated to avoid acting on. That patient exists in significant volume in most private practice markets and is actively searching for non-surgical options.

Where the Traditional Treatment Ladder Falls Short

Physical therapy, NSAIDs, and activity modification are appropriate first-line care and the right answer for patients who respond. For the cohort with persistent symptoms beyond six months and a visible deposit, conservative care alone rarely produces deposit resorption or full functional recovery.

Repeated cortisone injection reduces inflammation around the deposit but does not address the deposit itself. Most current guidance recommends limiting repeated injections in this setting given concerns about rotator cuff tendon integrity. 

Needle barbotage is an effective intervention with substantial published support. It requires ultrasound guidance and an experienced operator. Focused wave therapy produces comparable clinical outcomes in most published comparisons without the procedural complexity, which makes it more broadly accessible across practice types.

Arthroscopic removal is invasive, requires recovery, and carries the risks inherent to any shoulder arthroscopy. Current guidance supports trialing focused wave therapy before surgical intervention.

What This Means for Practice Development

Calcific tendinopathy is the right starting point for a practice integrating focused wave therapy. The reasons are practical.

The evidence base is the most defensible in the literature, which gives you a clear, documented position with patients, referring providers, and payers — not a speculative one. 

The imaging change is visible and documentable. Pre- and post-treatment films showing deposit resorption are among the most compelling patient communication tools a practice can generate. Providers who run this protocol consistently build a case library that does more for patient acquisition than any marketing asset they could produce.

The patient population is highly motivated and typically cash-pay. Chronic shoulder pain is debilitating. These patients have often already been through PT, cortisone, and a surgical referral they did not want to act on. They are willing to invest in a credible non-surgical alternative.

The referral position is durable. A practice known in its market as the calcific tendinopathy destination builds a referral pipeline that is difficult to replicate, because the combination of technology access and documented outcomes is not common.

Clinical and Provider Questions

When should a patient be referred to surgery instead?

Current guidance supports exhausting non-surgical options — including focused wave therapy — before arthroscopic removal. Surgery remains appropriate for patients who fail conservative and procedural care and whose symptoms continue to meaningfully limit function. The 2023 systematic review of 2,212 patients provides the evidence base for that recommendation.

How do you identify patients who will respond?

The published literature points toward stronger response in chronic cases with visible deposits greater than 5 mm, in patients who have already attempted conservative care, and in those who are motivated to complete the treatment course. Acute presentations sometimes resolve with conservative measures. Patient counseling should address both the clinical improvement timeline and the imaging timeline for deposit change — the latter typically assessed at 12 weeks and beyond.

Can focused wave therapy be used alongside partial-thickness rotator cuff tears?

The literature includes evidence for rotator cuff tendinopathy broadly, and partial-thickness tears are generally considered compatible with focused wave therapy in published series. Full-thickness tears, structural derangement, or instability warrant separate surgical evaluation.

What outcomes can you share with patients?

For chronic calcific tendinopathy specifically, published research supports approximately 70–88% improvement in pain and function across studies. Partial or complete calcium deposit resorption occurs in roughly 70–75% of treated patients in published series. 

Individual outcomes vary, and patients should be counseled on the realistic timeline for both clinical and imaging change.

What does a typical protocol look like?

Most published protocols use three to five sessions, spaced approximately one week apart, with energy levels titrated to patient tolerance. The specific approach depends on device characteristics, deposit size, and patient response.

The Bottom Line

Calcific tendinopathy of the shoulder is where focused acoustic wave therapy makes its strongest argument. The evidence spans pain, function, imaging-documented deposit resorption, and direct comparison to surgical intervention. No other musculoskeletal indication in the focused wave literature has the same depth or consistency.

For a private practice evaluating focused wave technology, this is the protocol to anchor around first — not because the others lack support, but because this one has the evidence, the patient population, and the clinical narrative to build a durable practice position from the start.

If you want to evaluate whether focused acoustic wave therapy fits your practice, the team walks through your current shoulder pain volume, your local referral landscape, and the financial model before any device decision is made.